This is a very significant point for Neuren. CNS is known as the graveyard of drug development. So many drugs have failed that many Pharma companies disbanded their CNS teams to stop wasting money on repeated failures.
This isn't because CNS isn't a big market (Alzheimers, stroke, TBI are all as big as you could get market wise), its because its been so hard to prove any benefits that outweigh side-effects.
The fact that Neuren may have one of the first approved neurodevelopment drugs that _also_ has potential for wider application in a CNS market with few successful drugs makes Neuren just that much more valuable.
Its easy to see why Jon struggles to contain his excitement about NNZ-2591. The facts above make Neuren's potential 'aspirin for the brain' inestimably more valuable.
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-21
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$15.39 |
Change
0.550(3.71%) |
Mkt cap ! $1.915B | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.50 | $14.91 | $9.641M | 631.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $15.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.39 | 1224 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |